Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
SynopsisI

Should a statin be routinely prescribed for primary prevention of cardiovascular disease in diabetes mellitus?

Daniel G. Hackam
CMAJ October 12, 2004 171 (8) 857; DOI: https://doi.org/10.1503/cmaj.1041490
Daniel G. Hackam
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading
  • © 2004 Canadian Medical Association or its licensors

Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HAW, Livingstone SJ, et al; CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96.

Background: HMG–CoA reductase inhibitors (statins) are effective in reducing the risk of cardiovascular events in patients with cardiovascular disease (CVD) or hypercholesterolemia. However, their effectiveness in the primary prevention of CVD in patients with type 2 diabetes and no history of atherosclerosis is less clear.

Design: This double-blind study enrolled 2838 patients aged 40– 75 with type 2 diabetes who had no known CVD but at least 1 additional cardiovascular risk factor (hypertension, retinopathy, albuminuria or current smoking). Patients were randomly allocated to receive placebo or 10 mg of atorvastatin daily. The primary outcome measure was the composite of acute coronary syndrome, coronary revascularization or stroke. All analyses were by intention-to-treat. The trial was ended 2 years early because of significant evidence of efficacy.

Results: The average participant was male (68%), was 62 years old, had medication-treated diabetes known for an average of 8 years, was overweight (mean body mass index 29) and had hypertension (84%). Control of blood glucose and glycated hemoglobin was poor, and only 1 in 7 patients was taking ASA or another antiplatelet drug at baseline; less than half received an angiotensin-converting-enzyme inhibitor. Study outcomes are summarized in Table 1. Treatment was safe and well tolerated.

View this table:
  • View inline
  • View popup
  • Download powerpoint

Table 1.

Commentary: At first glance, the data appear to support the authors' conclusion that most, if not all, patients with type 2 diabetes should be considered for long-term statin therapy. Indeed, the researchers went a long way toward proving their hypothesis: they excluded patients with known CVD (in whom benefit was already demonstrated); they used a low dose of a potent statin to maximize efficacy and minimize toxicity; and they enrolled many patients whose cholesterol levels were below current recommended treatment thresholds. However, the average participant had long-standing diabetes with multiple additional risk factors that were substantially undertreated. Thus, it remains to be seen whether the benefits would be realized in diabetic patients who did not have similar risk factors or who were optimally treated for their comorbidities. Also, the study excluded patients at extremes of age (< 40 and > 75), those with evidence of cardiac, renal or hepatic insufficiency, marked obesity (body mass index > 35), severely uncontrolled diabetes, suboptimal compliance, and those with any of a range of laboratory abnormalities. Thus, despite the authors' assertions, the generalizability of these results to all diabetic patients has not been established. Moreover, although the positive results of CARDS are congruent with those from a previous study,1 they differ from the findings among diabetic patients in 2 other major studies.2,3

Practice implications: Patients with diabetes are a heterogenous group with varying risks of cardiovascular events. Those with CVD should receive a statin regardless of their low-density lipoprotein cholesterol level, because of their extremely high risk for future events. For those without CVD, the clinician must still carefully consider the patient's baseline risk and personal preferences, as well as the expense and inconvenience of long-term treatment.

Daniel G. Hackam Division of Clinical Pharmacology Sunnybrook and Women's College Health Sciences Centre Toronto, Ont.

References

  1. 1.↵
    Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-16.
    OpenUrlCrossRefPubMed
  2. 2.↵
    Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial– Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58.
    OpenUrlCrossRefPubMed
  3. 3.↵
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002; 288:2998-3007.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 171 (8)
CMAJ
Vol. 171, Issue 8
12 Oct 2004
  • Table of Contents
  • Index by author
  • Canadian Adverse Reaction Newsletter (991-1102)

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Should a statin be routinely prescribed for primary prevention of cardiovascular disease in diabetes mellitus?
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Should a statin be routinely prescribed for primary prevention of cardiovascular disease in diabetes mellitus?
Daniel G. Hackam
CMAJ Oct 2004, 171 (8) 857; DOI: 10.1503/cmaj.1041490

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Should a statin be routinely prescribed for primary prevention of cardiovascular disease in diabetes mellitus?
Daniel G. Hackam
CMAJ Oct 2004, 171 (8) 857; DOI: 10.1503/cmaj.1041490
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • References
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • Highlights of this issue
  • Google Scholar

Cited By...

  • Challenges of teaching EBM
  • Google Scholar

More in this TOC Section

  • The changing ecology of avian flu
  • Applying the 2005 Canadian Hypertension Education Program recommendations: 4. Managing uncomplicated hypertension
  • A newborn requiring selective bronchial intubation
Show more Synopsis

Similar Articles

Collections

  • Topics
    • Cardiovascular medicine
    • Diabetes

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire